A Pan-Cancer Multi-Omics Analysis of CAD: Integrating CRISPR and Metabolomics Data to Unravel the Metabolic–Immune Axis and Immunotherapy Response
Yiyan Li, Aoxue Xing, Wenzheng Li, Yiman Zhang, Kejuan Zhang, Tianhao Xie, Gang Wu, Wei Zhang · 2026
Read A Pan-Cancer Multi-Omics Analysis of CAD: Integrating CRISPR and Metabolomics Data to Unravel the Metabolic–Immune Axis and Immunotherapy Response by Yiyan Li, Aoxue Xing, Wenzheng Li, Yiman Zhang, Kejuan Zhang, Tianhao Xie, Gang Wu, Wei Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13297017.txt.
Description
Yiyan Li and colleagues scan the CAD enzyme gene across many cancers in a 2026 multi-omics analysis. CAD runs the first steps of building pyrimidines, the letter molecules needed for DNA. Data from tumour atlases, cell-line screens, and metabolite studies were combined to judge its biomarker promise.
CAD ran high in seventeen cancer types, with strong diagnostic accuracy in a few of them. High levels tracked with features linked to initial immunotherapy response, yet also with worse long-term survival in pooled patient groups. Metabolite data tied high CAD to pyrimidine build-up and shifted amino-acid handling. The authors call CAD a candidate marker needing mechanistic and clinical validation.
Catalog record
| CREATOR | Yiyan Li, Aoxue Xing, Wenzheng Li, Yiman Zhang, Kejuan Zhang, Tianhao Xie, Gang Wu, Wei Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |